Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers

Biochemistry and Cell Biology

Volumn 91, Issue 6, 2013, Pages 419-427

  Damaraju, Vijaya L ^a   Mowles, Delores ^b   Wilson, Marnie ^b   Kuzma, Michelle ^b   Cass, Carol E ^a   Sawyer, Michael B ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Department of Experimental Oncology ^*  (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

Author keywords

membrane transport; nucleobases and cytotoxicity; nucleosides; renal cancer

Indexed keywords

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CELL LINE, TUMOR; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; FLOXURIDINE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN-ION CONCENTRATION; INTERFERON-ALPHA; KIDNEY TUBULES, PROXIMAL; KINETICS; NUCLEOSIDES; SIGNAL TRANSDUCTION; THYMIDINE PHOSPHORYLASE;

EID: 84894225793     PISSN: 08298211     EISSN: 12086002     Source Type: Journal    
DOI: 10.1139/bcb-2013-0041     Document Type: Article

References (40)

1. Baldwin S.A. Yao S.Y. Hyde R.J. Ng A.M. Foppolo S. Barnes K. et al 2005. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J. Biol. Chem. 280: 15880-15887. 10.1074/jbc.M414337200. 15701636.
2. Barnes K. Dobrzynski H. Foppolo S. Beal P.R. Ismat F. Scullion E.R. et al 2006. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ. Res. 99: 510-519. 10.1161/01.RES.0000238359.18495.42. 16873718.
3. Blackburn J.G. Hazen-Martin D.J. Detrisac C.J. Sens D.A. 1988. Electrophysiology and ultrastructure of cultured human proximal tubule cells. Kidney Int. 33: 508-516. 10.1038/ki.1988.27. 3361752.
4. Boleti H. Coe I.R. Baldwin S.A. Young J.D. Cass C.E. 1997. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology, 36: 1167-1179. 10.1016/S0028-3908(97)00136-6. 9364472.
5. Bone D.B. Hammond J.R. 2007. Nucleoside and nucleobase transporters of primary human cardiac microvascular endothelial cells: characterization of a novel nucleobase transporter. Am. J. Physiol. Heart Circ. Physiol. 293: H3325-H3332. 10.1152/ajpheart.01006.2007. 17921321.
6. De Mulder P.H. Weissbach L. Jakse G. Osieka R. Blatter J. 1996. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother. Pharmacol. 37: 491-495. 10.1007/s002800050417. 8599874.
7. Elwi A.N. Damaraju V.L. Kuzma M.L. Baldwin S.A. Young J.D. Sawyer M.B. et al 2009. Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures. Cancer Chemother. Pharmacol. 63: 289-301. 10.1007/s00280-008- 0739-1. 18500522.
8. Gati W.P. Paterson A.R. Tyrrell D.L. Cass C.E. Moravek J. Robins M.J. 1992. Nucleobase transporter-mediated permeation of 2′,3′- dideoxyguanosine in human erythrocytes and human T-lymphoblastoid CCRF-CEM cells. J. Biol. Chem. 267: 22272-22276. 1429579.
9. George C.M. Stadler W.M. 2003. The role of systemic chemotherapy in the treatment of kidney cancer. Cancer Treat. Res. 116: 173-182. 10.1007/978-1-4615-0451-1-10. 14650832.
10. Griffith D.A. Jarvis S.M. 1993. High affinity sodium-dependent nucleobase transport in cultured renal epithelial cells (LLC-PK1). J. Biol. Chem. 268: 20085-20090. 8376366.
11. Griffith D.A. Jarvis S.M. 1996. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta, 1286: 153-181. 10.1016/S0304-4157(96)00008-1. 8982282.
12. Griffiths M. Yao S.Y. Abidi F. Phillips S.E. Cass C.E. Young J.D. et al 1997. Molecular cloning and characterization of a nitrobenzylthioinosine- insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem. J. 328 (3): 739-743. 9396714.
13. Jonasch E. Lal L.S. Atkinson B.J. Byfield S.D. Miller L.A. Pagliaro L.C. et al 2011. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int. 107: 741-747. 10.1111/j.1464-410X.2010.09626.x. 21355978.
14. Judson I.R. Beale P.J. Trigo J.M. Aherne W. Crompton T. Jones D. et al 1999. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest. New Drugs, 17: 49-56. 10.1023/A:1006263400888. 10555122.
15. Kato R. Maeda T. Akaike T. Tamai I. 2006. Characterization of novel Na+-dependent nucleobase transport systems at the blood-testis barrier. Am. J. Physiol. Endocrinol. Metab. 290: E968-E975. 10.1152/ajpendo.00160.2005. 16368787.
16. Kish J.A. Wolf M. Crawford E.D. Leimert J.T. Bueschen A. Neefe J.R. et al 1994. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer, 74: 916-919. 10.1002/1097-0142(19940801)74:3<916::AID- CNCR2820740319>3.0.CO;2-Z. 8039119.
17. Koukourakis G.V. Kouloulias V. Koukourakis M.J. Zacharias G.A. Zabatis H. Kouvaris J. 2008. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules, 13: 1897-1922. 10.3390/molecules13081897. 18794792.
18. Kraupp M. Marz R. 1995. Nucleobase and nucleoside transport in mammalian cells. Wien. Klin. Wochenschr. 107: 677-680. 8533427.
19. Majumdar S. Tirucherai G.S. Pal D. Mitra A.K. 2003. Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS PharmSci. 5: E15. 12866942.
20. Mertens W.C. Eisenhauer E.A. Moore M. Venner P. Stewart D. Muldal A. et al 1993. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann. Oncol. 4: 331-332. 8518225.
21. Miwa M. Ura M. Nishida M. Sawada N. Ishikawa T. Mori K. et al 1998. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34: 1274-1281. 10.1016/S0959-8049(98)00058-6. 9849491.
22. Morita T. Tokue A. 1999. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Cancer Chemother. Pharmacol. 44: 91-96. 10.1007/s002800050951. 10412941.
23. Oudard S. 2010. More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus. Anticancer Res. 30: 5223-5225. 21187517.
24. Pastor-Anglada M. Cano-Soldado P. Errasti-Murugarren E. Casado F.J. 2008. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica, 38: 972-994. 10.1080/00498250802069096. 18668436.
25. Porta C. Paglino C. 2011. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int. 107: 747-748. 10.1111/j.1464-410X.2011.10154.x. 21355979.
26. Quashie N.B. Ranford-Cartwright L.C. de Koning H.P. 2010. Uptake of purines in Plasmodium falciparum-infected human erythrocytes is mostly mediated by the human equilibrative nucleoside transporter and the human facilitative nucleobase transporter. Malar. J. 9: 36. 10.1186/1475-2875-9-36. 20113503.
27. Reigner B. Blesch K. Weidekamm E. 2001. Clinical pharmacokinetics of capecitabine. Clin. Pharmacokinet. 40: 85-104. 10.2165/00003088-200140020-00002. 11286326.
28. Rini B.I. Vogelzang N.J. Dumas M.C. Wade J.L. III Taber D.A. Stadler W.M. 2000. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J. Clin. Oncol. 18: 2419-2426. 10856102.
29. Ritzel M.W. Yao S.Y. Huang M.Y. Elliott J.F. Cass C.E. Young J.D. 1997. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am. J. Physiol. 272: C707-C714. 9124315.
30. Ritzel M.W. Yao S.Y. Ng A.M. Mackey J.R. Cass C.E. Young J.D. 1998. Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol. Membr. Biol. 15: 203-211. 10.3109/ 09687689709044322. 10087507.
31. Ritzel M.W. Ng A.M. Yao S.Y. Graham K. Loewen S.K. Smith K.M. et al 2001. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem. 276: 2914-2927. 10.1074/jbc.M007746200. 11032837.
32. Santi D.V. McHenry C.S. Sommer H. 1974. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry, 13: 471-481. 10.1021/bi00700a012. 4203910.
33. Shayeghi M. Akerman R. Jarvis S.M. 1999. Nucleobase transport in opossum kidney epithelial cells and Xenopus laevis oocytes: the characterisation, structure-activity relationship of uracil analogues and oocyte expression studies of sodium-dependent and-independent hypoxanthine uptake. Biochim. Biophys. Acta, 1416: 109-118. 10.1016/S0005-2736(98)00213-2. 9889340.
34. Srivastava S.K. Beutler E. 1971. Purification and kinetic studies of adenine phosphoribosyltransferase from human erythrocytes. Arch. Biochem. Biophys. 142: 426-434. 10.1016/0003-9861(71)90506-6. 4323725.
35. Theisinger A. Grenacher B. Scharrer E. 2003. Na+ gradient-dependent transport of hypoxanthine by calf intestinal brush border membrane vesicles. J. Comp. Physiol. B, 173: 165-170. 10.1007/s00360-002-0324-6. 12624654.
36. Tsimafeyeu I. Demidov L. Kharkevich G. Petenko N. Galchenko V. Sinelnikov I. et al 2012. Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma. Am. J. Clin. Oncol. 35: 251-254. 10.1097/COC.0b013e31820dbc17. 21358295.
37. Ullman B. Patrick J. McCartan K. 1987. Expression of the high-affinity purine nucleobase transporter in mutant mouse S49 cells does not require a functional wild-type nucleoside-nucleobase transporter. Mol. Cell. Biol. 7: 97-103. 3561404.
38. Wood L. 2012. Sunitinib malate for the treatment of renal cell carcinoma. Expert Opin. Pharmacother. 13: 1323-1336. 10.1517/14656566.2012.689130. 22607009.
39. Yao S.Y. Ng A.M. Vickers M.F. Sundaram M. Cass C.E. Baldwin S.A. et al 2002. Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. J. Biol. Chem. 277: 24938-24948. 10.1074/jbc.M200966200. 12006583.
40. Young J.D. Yao S.Y. Sun L. Cass C.E. Baldwin S.A. 2008. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica, 38: 995-1021. 10.1080/00498250801927427. 18668437.